Amyloid-beta protofibrils — Drug Target

All drugs that target Amyloid-beta protofibrils — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Monoclonal antibody (anti-amyloid-beta)

Phase 3 pipeline (3)

• Lecanemab IV · Eisai Inc. · Monoclonal antibody (anti-amyloid-beta) · Neurology
  Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.
• Lecanemab SC · Eisai Inc. · Monoclonal antibody (anti-amyloid-beta) · Neurology
  Lecanemab is a monoclonal antibody that binds to amyloid-beta protofibrils and promotes their clearance from the brain.
• ABP 692 · Amgen · Monoclonal antibody (anti-amyloid-beta) · Neurology
  ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease.